IMRX · NASDAQ
Immuneering (IMRX) Stock Price & Fundamentals
Immuneering (IMRX) closed at $220.17 on Oct 9, 2026, down 0.85% from the previous close of $222.06.
Share price, past year
1Y +4.36%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $220.17 |
| Sep 30, 2026 | $221.76 |
| Aug 31, 2026 | $235.09 |
| Jul 31, 2026 | $225.98 |
| Jun 30, 2026 | $214.41 |
| May 29, 2026 | $218.77 |
| Apr 30, 2026 | $209.57 |
| Mar 31, 2026 | $215.74 |
| Feb 27, 2026 | $223.12 |
| Jan 30, 2026 | $220.22 |
| Dec 31, 2025 | $223.60 |
| Nov 28, 2025 | $222.34 |
| Oct 31, 2025 | $219.99 |
Key statistics
- Market cap
- —
- P/E (TTM)
- —
- EPS (TTM)
- −$0.93
- Revenue (TTM)
- —
- Net income (TTM)
- −$57.28M
- Shares outstanding
- —
- Dividend yield
- —
- 52-week range
- $207.80 – $235.30
Financials
Immuneering reported revenue of $0.00 for fiscal 2023, down 100.00% from fiscal 2022.
Immuneering reported a net loss of $56.02M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2023ended Dec 31, 2023 | $0.00 | −100.0% | −$53.47M | — | −$1.88 | −$49.31M |
| FY2022ended Dec 31, 2022 | $316.95K | −84.8% | −$50.51M | −15,937.3% | −$1.91 | −$44.84M |
| FY2021ended Dec 31, 2021 | $2.08M | −10.0% | −$33.54M | −1,612.3% | −$2.46 | −$30.91M |
| FY2020ended Dec 31, 2020 | $2.31M | — | −$17.04M | −737.2% | −$3.44 | −$14.67M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q4 FY2023ended Dec 31, 2023 | $0.00 | — | — |
| Q3 FY2023ended Sep 30, 2023 | $0.00 | — | — |
| Q2 FY2023ended Jun 30, 2023 | $0.00 | — | — |
| Q1 FY2023ended Mar 31, 2023 | $0.00 | — | — |
| Q4 FY2022ended Dec 31, 2022 | $455.00 | — | — |
| Q3 FY2022ended Sep 30, 2022 | $38.38K | — | — |
| Q2 FY2022ended Jun 30, 2022 | $94.42K | — | — |
| Q1 FY2022ended Mar 31, 2022 | $183.70K | — | — |
Company profile
- Name
- Immuneering Corp
- Ticker
- IMRX
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 245 Main Street, Second Floor, Cambridge, MA 02142
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001790340
Recent SEC filings
- Aug 5, 2026
- Aug 5, 2026
- Jun 15, 2026
- Jun 11, 2026
- Jun 1, 2026
- May 15, 2026
- May 15, 2026
- Mar 6, 2026
Frequently asked questions
What is Immuneering's stock price?
Immuneering (IMRX) closed at $220.17 on Oct 9, 2026, down 0.85% from the previous close of $222.06.
How much revenue does Immuneering make?
Immuneering reported revenue of $0.00 for fiscal 2023, down 100.00% from fiscal 2022.
Does Immuneering pay a dividend?
Immuneering's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Immuneering Corp's filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures